US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

0.7238

+0.00280.39%

Post-market: 0.7100-0.0138-1.91%19:28 EST

Volume:87.46K

Turnover:64.68K

Market Cap:23.20M

PE:-0.56

High:0.7586

Open:0.7198

Low:0.7198

Close:0.7210

52wk High:5.75

52wk Low:0.6844

Shares:32.06M

Float Shares:19.69M

Volume Ratio:0.26

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2914

EPS(LYR):-0.7281

ROE:-94.31%

ROA:-54.88%

PB:0.71

PE(LYR):-0.99

Loading ...

Overview Company News Filings

BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab

Skye Bioscience Reports 22% Weight Loss at 52 Weeks With Nimacimab and Semaglutide Combination in Phase 2a Study

Skye Bioscience Inc - 22.3% Weight Loss at 52 Weeks With Nimacimab + Semaglutide (2.4 Mg) Combination

THOMSON REUTERS

Skye Bioscience Inc - Full Topline Reporting of Cbeyond Phase 2a Data Expected Q3 2026

THOMSON REUTERS

Skye Reports Positive Cbeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

THOMSON REUTERS

Skye Bioscience presents poster on efficacy of Nimacimab

Skye Bioscience Launches Phase 2a Trial of Nimacimab for Obesity Treatment

Analysts Offer Insights on Healthcare Companies: TNL Mediagene (TNMG) and Skye Bioscience (SKYE)

Skye Bioscience to Launch Phase 2b Trial of Nimacimab for Obesity in Q3 2026

Skye Provides 2026 Corporate Outlook

THOMSON REUTERS

Skye Bioscience Inc - Phase 2B Cbeyond 2 Trial Launch Targeted for Q3 2026

THOMSON REUTERS

Skye Bioscience Inc - Cbeyond Phase 2a Topline Results Expected Q3 2026

THOMSON REUTERS

Investors File Class Action Lawsuit Against Skye Bioscience

BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group

BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive

BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug

Skye Bioscience Inc: Skye Is Planning to Initiate a Phase 2B Clinical Trial in Obesity for Nimacimab With Enhanze in Middle of 2026

THOMSON REUTERS

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated With Enhanze® for Obesity

THOMSON REUTERS

Halozyme Therapeutics Inc - Skye Plans Phase 2B Trial for Nimacimab in Mid-2026

THOMSON REUTERS

Skye Bioscience Inc - on Dec 18, Enters Collaboration Agreement With Halozyme - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SKYE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":0.7238,"timestamp":1771016400000,"preClose":0.721,"halted":0,"volume":87463,"hourTrading":{"tag":"盘后","latestPrice":0.71,"preClose":0.7238,"latestTime":"19:28 EST","volume":225,"amount":162.6015,"timestamp":1771028928473,"change":-0.0138,"changeRate":-0.019066,"amplitude":0.019066},"delay":0,"changeRate":0.0038834951456311025,"floatShares":19689100,"shares":32057500,"eps":-1.291415,"marketStatus":"Not Yet Opened","change":0.0028,"latestTime":"02-13 16:00:00 EST","open":0.7198,"high":0.7586,"low":0.7198,"amount":64684.6698043,"amplitude":0.053814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.291415,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":0,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":0.721,"preHourTrading":{"tag":"盘前","latestPrice":0.73,"preClose":0.721,"latestTime":"09:27 EST","volume":826,"amount":603.0530183999999,"timestamp":1770992859492,"change":0.009,"changeRate":0.012483,"amplitude":0.02025},"postHourTrading":{"tag":"盘后","latestPrice":0.71,"preClose":0.7238,"latestTime":"19:28 EST","volume":225,"amount":162.6015,"timestamp":1771028928473,"change":-0.0138,"changeRate":-0.019066,"amplitude":0.019066},"volumeRatio":0.26325421125121007,"impliedVol":1.1162,"impliedVolPercentile":0.2988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":19689100,"roa":"-54.88%","roe":"-94.31%","lyrEps":-0.728135,"volumeRatio":0.26325421125121007,"shares":32057500,"dividePrice":0,"high":0.7586,"amplitude":0.053814,"preClose":0.721,"low":0.7198,"week52Low":0.6844,"pbRate":"0.71","week52High":5.75,"institutionHeld":0,"latestPrice":0.7238,"eps":-1.291415,"divideRate":0,"volume":87463,"delay":0,"ttmEps":-1.291415,"open":0.7198,"prevYearClose":0.7497,"prevWeekClose":0.7238,"prevMonthClose":1.01,"prevQuarterClose":0.7497,"fiveDayClose":0.8193,"twentyDayClose":0.9626,"sixtyDayClose":1.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"SKYE","fiscalQuarterEnding":"2025/09","expectedEps":-0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-07","symbol":"SKYE","fiscalQuarterEnding":"2025/06","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-11-07","symbol":"SKYE","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1759899600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2026-02-13","current":-0.56047,"percent":0.997753,"low":-12.94129,"twenty":-4.684882,"median":-3.355987,"eighty":-1.389518,"high":-0.450738,"avg":-3.626802,"sd":2.545357,"marketCap":23113429},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369},{"date":"2025-06-13","current":-2.05924,"twenty":-6.976473,"median":-4.013573,"eighty":-2.54373,"marketCap":67236056},{"date":"2025-06-20","current":-2.030771,"twenty":-6.805634,"median":-3.979786,"eighty":-2.387759,"marketCap":66306526},{"date":"2025-06-27","current":-4.033073,"twenty":-6.650207,"median":-3.970723,"eighty":-2.387759,"marketCap":131683521},{"date":"2025-07-03","current":-4.374698,"twenty":-6.513129,"median":-3.970723,"eighty":-2.471704,"marketCap":142837890},{"date":"2025-07-11","current":-3.738896,"twenty":-6.413147,"median":-3.970723,"eighty":-2.503792,"marketCap":122078370},{"date":"2025-07-18","current":-3.530125,"twenty":-6.413147,"median":-3.966646,"eighty":-2.541658,"marketCap":115261811},{"date":"2025-07-25","current":-3.805323,"twenty":-6.298881,"median":-3.947535,"eighty":-2.546837,"marketCap":124247275},{"date":"2025-08-01","current":-3.387782,"twenty":-6.198899,"median":-3.902759,"eighty":-2.561185,"marketCap":110614158},{"date":"2025-08-08","current":-3.368802,"twenty":-6.1132,"median":-3.885025,"eighty":-2.56836,"marketCap":109994470},{"date":"2025-08-15","current":-2.391434,"twenty":-6.1132,"median":-3.856458,"eighty":-2.546837,"marketCap":101332133},{"date":"2025-08-22","current":-2.596205,"twenty":-6.1132,"median":-3.856458,"eighty":-2.541658,"marketCap":110008891},{"date":"2025-08-29","current":-2.545012,"twenty":-6.033244,"median":-3.838191,"eighty":-2.530385,"marketCap":107839701},{"date":"2025-09-05","current":-2.74247,"twenty":-6.003302,"median":-3.805323,"eighty":-2.498872,"marketCap":116206575},{"date":"2025-09-12","current":-3.115445,"twenty":-5.964031,"median":-3.793648,"eighty":-2.525066,"marketCap":132010669},{"date":"2025-09-19","current":-2.881421,"twenty":-5.898952,"median":-3.776855,"eighty":-2.539403,"marketCap":122094374},{"date":"2025-09-26","current":-2.632771,"twenty":-5.861816,"median":-3.757875,"eighty":-2.544341,"marketCap":111558312},{"date":"2025-10-03","current":-3.28365,"twenty":-5.684705,"median":-3.738896,"eighty":-2.546472,"marketCap":139138005},{"date":"2025-10-10","current":-1.257879,"twenty":-5.595667,"median":-3.729992,"eighty":-2.525066,"marketCap":53300082},{"date":"2025-10-17","current":-1.060422,"twenty":-5.58412,"median":-3.727909,"eighty":-2.468814,"marketCap":44933209},{"date":"2025-10-24","current":-1.060422,"twenty":-5.516043,"median":-3.699343,"eighty":-2.388509,"marketCap":44933209},{"date":"2025-10-31","current":-1.075048,"twenty":-5.447334,"median":-3.691448,"eighty":-2.317303,"marketCap":45552977},{"date":"2025-11-07","current":-1.111614,"twenty":-5.371836,"median":-3.676368,"eighty":-2.244599,"marketCap":47102398},{"date":"2025-11-14","current":-0.828708,"twenty":-5.321912,"median":-3.651662,"eighty":-2.178806,"marketCap":42454135},{"date":"2025-11-21","current":-0.782205,"twenty":-5.233356,"median":-3.64221,"eighty":-2.124921,"marketCap":40071826},{"date":"2025-11-28","current":-0.819751,"twenty":-5.18765,"median":-3.621859,"eighty":-2.093402,"marketCap":41995273},{"date":"2025-12-05","current":-0.757174,"twenty":-5.110521,"median":-3.608617,"eighty":-2.055444,"marketCap":38789527},{"date":"2025-12-12","current":-0.719628,"twenty":-5.037066,"median":-3.577936,"eighty":-2.025264,"marketCap":36866080},{"date":"2025-12-19","current":-0.625701,"twenty":-4.9588,"median":-3.549105,"eighty":-1.981949,"marketCap":32054255},{"date":"2025-12-26","current":-0.522137,"twenty":-4.912548,"median":-3.544049,"eighty":-1.945365,"marketCap":26748745},{"date":"2026-01-02","current":-0.469135,"twenty":-4.89913,"median":-3.530125,"eighty":-1.880836,"marketCap":24033478},{"date":"2026-01-09","current":-0.657052,"twenty":-4.893905,"median":-3.501657,"eighty":-1.841207,"marketCap":33660334},{"date":"2026-01-16","current":-0.60236,"twenty":-4.863947,"median":-3.501004,"eighty":-1.780246,"marketCap":30858511},{"date":"2026-01-23","current":-0.657052,"twenty":-4.827714,"median":-3.463671,"eighty":-1.698098,"marketCap":33660334},{"date":"2026-01-30","current":-0.600733,"twenty":-4.820607,"median":-3.430485,"eighty":-1.632257,"marketCap":30775162},{"date":"2026-02-06","current":-0.500298,"twenty":-4.784865,"median":-3.387782,"eighty":-1.562303,"marketCap":25629940},{"date":"2026-02-13","current":-0.451176,"twenty":-4.684882,"median":-3.355987,"eighty":-1.389518,"marketCap":23113429}],"updateTime":1771302156572},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608765866","title":"BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2608765866","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608765866?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:26","pubTimestamp":1770035179,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For NimacimabFeb 2 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2608586571","title":"Skye Bioscience Reports 22% Weight Loss at 52 Weeks With Nimacimab and Semaglutide Combination in Phase 2a Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2608586571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608586571?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:01","pubTimestamp":1770033708,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. announced interim 52-week data from the extension phase of its Phase 2a CBeyond proof-of-concept study evaluating nimacimab, a peripherally-restricted CB1 inhibitor antibody, in combination with semaglutide for obesity and metabolic disorders. The results showed a 22.3% total weight loss at 52 weeks for the combination of nimacimab  and semaglutide , with no plateau observed, suggesting the potential for continued efficacy beyond one year and at higher nimacimab doses. The combination also demonstrated a reduction in weight regain during a 13-week treatment interruption, with participants regaining 17.8% of weight lost compared to 37.3% for semaglutide alone. The safety and tolerability profile remained strong, with no serious adverse events reported. Full topline data, including nimacimab monotherapy results and off-therapy follow-up, are expected to be reported in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6qrSg5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","SKYE","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2608786528","title":"Skye Bioscience Inc - 22.3% Weight Loss at 52 Weeks With Nimacimab + Semaglutide (2.4 Mg) Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2608786528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608786528?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2608586528","title":"Skye Bioscience Inc - Full Topline Reporting of Cbeyond Phase 2a Data Expected Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608586528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608586528?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2608243865","title":"Skye Reports Positive Cbeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2608243865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608243865?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2607842690","title":"Skye Bioscience presents poster on efficacy of Nimacimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2607842690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607842690?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:20","pubTimestamp":1769689216,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Mainte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-presents-poster-on-efficacy-of-nimacimab-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-presents-poster-on-efficacy-of-nimacimab-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2605673101","title":"Skye Bioscience Launches Phase 2a Trial of Nimacimab for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2605673101","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605673101?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:00","pubTimestamp":1768996841,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has announced the presentation of new research on its peripherally-restricted CB1-inhibitor antibody, nimacimab, at the Keystone Obesity Therapeutics conference. The study investigates nimacimab’s efficacy alone, in combination with tirzepatide, and as a maintenance therapy following tirzepatide discontinuation in a diet-induced obesity mouse model. The research also examines whether caloric restriction is the primary mechanism behind nimacimab-driven weight loss. Results from this study are scheduled to be presented on January 28, 2026, during Poster Session 2 . Nimacimab is being developed as a potential first-in-class therapeutic for obesity and metabolic health disorders, and is currently being evaluated in a Phase 2a clinical trial for obesity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL1cwDHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SKYE","SG9999014021.USD","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4139","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2603883979","title":"Analysts Offer Insights on Healthcare Companies: TNL Mediagene (TNMG) and Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603883979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603883979?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:10","pubTimestamp":1768482649,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TNL Mediagene (TNMG – Research Report) and Skye Bi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tnl-mediagene-tnmg-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tnl-mediagene-tnmg-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNL","BK4137","HCSG","LU0128526141.USD","BK4588","XBI","LABU","SKYE","XLV","BK4142","BK4139","LU0029874061.USD","BK4585","BK4581"],"gpt_icon":0},{"id":"2602514197","title":"Skye Bioscience to Launch Phase 2b Trial of Nimacimab for Obesity in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514197","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514197?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:02","pubTimestamp":1768219357,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has announced its 2026 corporate outlook, detailing upcoming clinical milestones for its peripherally restricted CB1-inhibiting antibody, nimacimab, aimed at treating obesity and metabolic health disorders. Key clinical objectives for 2026 include an interim data update from the CBeyond Phase 2a 26-week extension, expected in the first quarter of 2026, and topline results covering 52 weeks with a 13-week off-therapy follow-up period, anticipated in the third quarter of 2026. Additionally, the company plans to finalize and initiate a Phase 2b  adaptive design clinical trial in the third quarter of 2026, following alignment with regulators. These results have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6jg2XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","BK4585","SG9999014039.USD","BK4139","SKYE","LU2210150020.SGD"],"gpt_icon":0},{"id":"2602514546","title":"Skye Provides 2026 Corporate Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514546?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUACXQ1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2602046514","title":"Skye Bioscience Inc - Phase 2B Cbeyond 2 Trial Launch Targeted for Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602046514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602046514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUACXQ1R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2602040514","title":"Skye Bioscience Inc - Cbeyond Phase 2a Topline Results Expected Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602040514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602040514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUACXQ1R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2601853672","title":"Investors File Class Action Lawsuit Against Skye Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2601853672","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601853672?lang=en_us&edition=fundamental","pubTime":"2026-01-06 07:00","pubTimestamp":1767654022,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc. on behalf of investors who claim to have suffered losses due to alleged securities fraud between November 4, 2024 and October 3, 2025. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing shareholders in securities litigation. Investors who incurred losses during the specified period are encouraged to seek more information and consider joining the class action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4T1D8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2601313638","title":"BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2601313638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601313638?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:47","pubTimestamp":1767638851,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","OKTA","WMB","QXO","SPIR","OMC","HL","GHRS","LBRT","EOG","SLB","RIOT","NOC","COP","EBC","MPC","HCA","AVY","RMTI","SKYE","SYF","BAC","ANET","HAL","BKR","ALT","CNX","DPZ","MBLY","CVS","INCY","CNC","LMT","SATL","LCID","AVAV","BKSY","NEM","ALB","SCCO"],"gpt_icon":1},{"id":"2601460882","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive","url":"https://stock-news.laohu8.com/highlight/detail?id=2601460882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601460882?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:14","pubTimestamp":1767622447,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCCO","OKTA","GOOGL","SLB","RIOT","ARDT","SATL","CDE","HAL","ALRS","KBR","SGHT","NMRA","ALT","SPIR","ANET","STX","IBM","SKYE","ALB","GHRS","HL","MBLY","BKR","FTV","EBC","THC","COP","EOG","HCA","RMTI","OMC","NEM","FIVN","LBRT","AZO","BKSY","DUOL","INCY","DVN"],"gpt_icon":1},{"id":"2601788664","title":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601788664","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601788664?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:13","pubTimestamp":1767615228,"startTime":"0","endTime":"0","summary":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug** Shares of drug developer Skye Bioscience SKYE.O rise 4.76% to $0.92 premarket** Co says it has signed a global agreement with Halozyme Therapeutics HALO.O to develop and potentially commercialize a new obesity treatment** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE** Co plans mid-stage trial of new formulation in mid-2026** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE** As of last close, stock up ~17% over the past year  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y60SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","HALO","BK4139","SKYE"],"gpt_icon":0},{"id":"2601885098","title":"Skye Bioscience Inc:  Skye Is Planning to Initiate a Phase 2B Clinical Trial in Obesity for Nimacimab With Enhanze in Middle of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885098?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614418,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60HA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","LU0053671581.USD","SKYE","BK4139"],"gpt_icon":0},{"id":"2601885793","title":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated With Enhanze® for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885793?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2R2D2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","LU0053671581.USD","BK4139","SKYE"],"gpt_icon":0},{"id":"2601588503","title":"Halozyme Therapeutics Inc - Skye Plans Phase 2B Trial for Nimacimab in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588503?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2R2D2B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"2593448072","title":"Skye Bioscience Inc - on Dec 18, Enters Collaboration Agreement With Halozyme - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448072?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:07","pubTimestamp":1766524025,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":63,"code":"91000000","status":"200"}]}}